nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—lung cancer	0.332	1	CbGaD
Scopolamine—ABCB1—Topotecan—lung cancer	0.0531	0.136	CbGbCtD
Scopolamine—ABCB1—Gefitinib—lung cancer	0.0485	0.124	CbGbCtD
Scopolamine—ABCB1—Vinorelbine—lung cancer	0.0374	0.0958	CbGbCtD
Scopolamine—ABCB1—Crizotinib—lung cancer	0.0298	0.0762	CbGbCtD
Scopolamine—ABCB1—Gemcitabine—lung cancer	0.0291	0.0745	CbGbCtD
Scopolamine—ABCB1—Erlotinib—lung cancer	0.0287	0.0735	CbGbCtD
Scopolamine—ABCB1—Paclitaxel—lung cancer	0.0263	0.0673	CbGbCtD
Scopolamine—ABCB1—Irinotecan—lung cancer	0.0259	0.0664	CbGbCtD
Scopolamine—ABCB1—Vinblastine—lung cancer	0.023	0.059	CbGbCtD
Scopolamine—ABCB1—Cisplatin—lung cancer	0.0211	0.0541	CbGbCtD
Scopolamine—ABCB1—Etoposide—lung cancer	0.0208	0.0532	CbGbCtD
Scopolamine—ABCB1—Docetaxel—lung cancer	0.019	0.0486	CbGbCtD
Scopolamine—ABCB1—Doxorubicin—lung cancer	0.0142	0.0363	CbGbCtD
Scopolamine—ABCB1—Methotrexate—lung cancer	0.0137	0.0351	CbGbCtD
Scopolamine—Constipation—Vinorelbine—lung cancer	0.000351	0.00185	CcSEcCtD
Scopolamine—Pain—Vinorelbine—lung cancer	0.000351	0.00185	CcSEcCtD
Scopolamine—Arrhythmia—Paclitaxel—lung cancer	0.000347	0.00183	CcSEcCtD
Scopolamine—Asthenia—Topotecan—lung cancer	0.000345	0.00181	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000342	0.0018	CcSEcCtD
Scopolamine—Confusional state—Irinotecan—lung cancer	0.000342	0.0018	CcSEcCtD
Scopolamine—Asthenia—Erlotinib—lung cancer	0.000341	0.00179	CcSEcCtD
Scopolamine—Mental disorder—Paclitaxel—lung cancer	0.000341	0.00179	CcSEcCtD
Scopolamine—Pruritus—Topotecan—lung cancer	0.00034	0.00179	CcSEcCtD
Scopolamine—Oedema—Irinotecan—lung cancer	0.000339	0.00178	CcSEcCtD
Scopolamine—Erythema—Paclitaxel—lung cancer	0.000339	0.00178	CcSEcCtD
Scopolamine—Feeling abnormal—Vinorelbine—lung cancer	0.000338	0.00178	CcSEcCtD
Scopolamine—Pruritus—Erlotinib—lung cancer	0.000336	0.00177	CcSEcCtD
Scopolamine—Nervous system disorder—Irinotecan—lung cancer	0.000332	0.00175	CcSEcCtD
Scopolamine—Eczema—Doxorubicin—lung cancer	0.000331	0.00174	CcSEcCtD
Scopolamine—Oedema—Gemcitabine—lung cancer	0.00033	0.00174	CcSEcCtD
Scopolamine—Irritability—Methotrexate—lung cancer	0.000328	0.00172	CcSEcCtD
Scopolamine—Hyperhidrosis—Irinotecan—lung cancer	0.000327	0.00172	CcSEcCtD
Scopolamine—Pharyngitis—Docetaxel—lung cancer	0.000327	0.00172	CcSEcCtD
Scopolamine—Dizziness—Vinblastine—lung cancer	0.000327	0.00172	CcSEcCtD
Scopolamine—Urinary tract disorder—Docetaxel—lung cancer	0.000326	0.00171	CcSEcCtD
Scopolamine—Abdominal pain—Vinorelbine—lung cancer	0.000325	0.00171	CcSEcCtD
Scopolamine—Body temperature increased—Vinorelbine—lung cancer	0.000325	0.00171	CcSEcCtD
Scopolamine—Nervous system disorder—Gemcitabine—lung cancer	0.000324	0.0017	CcSEcCtD
Scopolamine—Urethral disorder—Docetaxel—lung cancer	0.000323	0.0017	CcSEcCtD
Scopolamine—Skin disorder—Gemcitabine—lung cancer	0.000321	0.00169	CcSEcCtD
Scopolamine—Vision blurred—Paclitaxel—lung cancer	0.000319	0.00168	CcSEcCtD
Scopolamine—Hyperhidrosis—Gemcitabine—lung cancer	0.000319	0.00168	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000319	0.00168	CcSEcCtD
Scopolamine—Visual impairment—Docetaxel—lung cancer	0.000318	0.00167	CcSEcCtD
Scopolamine—Dizziness—Topotecan—lung cancer	0.000318	0.00167	CcSEcCtD
Scopolamine—Tremor—Paclitaxel—lung cancer	0.000317	0.00167	CcSEcCtD
Scopolamine—Hypotension—Irinotecan—lung cancer	0.000317	0.00166	CcSEcCtD
Scopolamine—Vomiting—Vinblastine—lung cancer	0.000314	0.00165	CcSEcCtD
Scopolamine—Dizziness—Erlotinib—lung cancer	0.000314	0.00165	CcSEcCtD
Scopolamine—Agitation—Paclitaxel—lung cancer	0.000311	0.00164	CcSEcCtD
Scopolamine—Vertigo—Etoposide—lung cancer	0.00031	0.00163	CcSEcCtD
Scopolamine—Headache—Vinblastine—lung cancer	0.00031	0.00163	CcSEcCtD
Scopolamine—Hypotension—Gemcitabine—lung cancer	0.000308	0.00162	CcSEcCtD
Scopolamine—Eye disorder—Docetaxel—lung cancer	0.000308	0.00162	CcSEcCtD
Scopolamine—Oedema—Cisplatin—lung cancer	0.000308	0.00162	CcSEcCtD
Scopolamine—Flushing—Docetaxel—lung cancer	0.000306	0.00161	CcSEcCtD
Scopolamine—Vomiting—Topotecan—lung cancer	0.000305	0.00161	CcSEcCtD
Scopolamine—Vertigo—Paclitaxel—lung cancer	0.000304	0.0016	CcSEcCtD
Scopolamine—Rash—Topotecan—lung cancer	0.000303	0.00159	CcSEcCtD
Scopolamine—Dermatitis—Topotecan—lung cancer	0.000302	0.00159	CcSEcCtD
Scopolamine—Vomiting—Erlotinib—lung cancer	0.000302	0.00159	CcSEcCtD
Scopolamine—Nervous system disorder—Cisplatin—lung cancer	0.000302	0.00159	CcSEcCtD
Scopolamine—Somnolence—Irinotecan—lung cancer	0.000301	0.00158	CcSEcCtD
Scopolamine—Headache—Topotecan—lung cancer	0.000301	0.00158	CcSEcCtD
Scopolamine—Tachycardia—Cisplatin—lung cancer	0.0003	0.00158	CcSEcCtD
Scopolamine—Rash—Erlotinib—lung cancer	0.0003	0.00158	CcSEcCtD
Scopolamine—Dermatitis—Erlotinib—lung cancer	0.000299	0.00157	CcSEcCtD
Scopolamine—Skin disorder—Cisplatin—lung cancer	0.000299	0.00157	CcSEcCtD
Scopolamine—Headache—Erlotinib—lung cancer	0.000298	0.00157	CcSEcCtD
Scopolamine—Hyperhidrosis—Cisplatin—lung cancer	0.000297	0.00156	CcSEcCtD
Scopolamine—Asthenia—Vinorelbine—lung cancer	0.000295	0.00155	CcSEcCtD
Scopolamine—Arrhythmia—Docetaxel—lung cancer	0.000294	0.00155	CcSEcCtD
Scopolamine—Nausea—Vinblastine—lung cancer	0.000294	0.00154	CcSEcCtD
Scopolamine—Somnolence—Gemcitabine—lung cancer	0.000293	0.00154	CcSEcCtD
Scopolamine—Fatigue—Irinotecan—lung cancer	0.000292	0.00154	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000292	0.00154	CcSEcCtD
Scopolamine—Pruritus—Vinorelbine—lung cancer	0.000291	0.00153	CcSEcCtD
Scopolamine—Pain—Irinotecan—lung cancer	0.00029	0.00152	CcSEcCtD
Scopolamine—Constipation—Irinotecan—lung cancer	0.00029	0.00152	CcSEcCtD
Scopolamine—Mental disorder—Docetaxel—lung cancer	0.000289	0.00152	CcSEcCtD
Scopolamine—Hypotension—Cisplatin—lung cancer	0.000287	0.00151	CcSEcCtD
Scopolamine—Erythema—Docetaxel—lung cancer	0.000287	0.00151	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000286	0.00151	CcSEcCtD
Scopolamine—Nausea—Topotecan—lung cancer	0.000285	0.0015	CcSEcCtD
Scopolamine—Fatigue—Gemcitabine—lung cancer	0.000284	0.0015	CcSEcCtD
Scopolamine—Confusional state—Etoposide—lung cancer	0.000284	0.00149	CcSEcCtD
Scopolamine—Constipation—Gemcitabine—lung cancer	0.000282	0.00148	CcSEcCtD
Scopolamine—Pain—Gemcitabine—lung cancer	0.000282	0.00148	CcSEcCtD
Scopolamine—Nausea—Erlotinib—lung cancer	0.000282	0.00148	CcSEcCtD
Scopolamine—Dry mouth—Paclitaxel—lung cancer	0.000282	0.00148	CcSEcCtD
Scopolamine—Feeling abnormal—Irinotecan—lung cancer	0.000279	0.00147	CcSEcCtD
Scopolamine—Confusional state—Paclitaxel—lung cancer	0.000279	0.00147	CcSEcCtD
Scopolamine—Dysuria—Methotrexate—lung cancer	0.000278	0.00146	CcSEcCtD
Scopolamine—Oedema—Paclitaxel—lung cancer	0.000276	0.00145	CcSEcCtD
Scopolamine—Tachycardia—Etoposide—lung cancer	0.000275	0.00145	CcSEcCtD
Scopolamine—Skin disorder—Etoposide—lung cancer	0.000274	0.00144	CcSEcCtD
Scopolamine—Dry skin—Doxorubicin—lung cancer	0.000273	0.00143	CcSEcCtD
Scopolamine—Hyperhidrosis—Etoposide—lung cancer	0.000272	0.00143	CcSEcCtD
Scopolamine—Feeling abnormal—Gemcitabine—lung cancer	0.000272	0.00143	CcSEcCtD
Scopolamine—Dizziness—Vinorelbine—lung cancer	0.000272	0.00143	CcSEcCtD
Scopolamine—Nervous system disorder—Paclitaxel—lung cancer	0.000271	0.00143	CcSEcCtD
Scopolamine—Tachycardia—Paclitaxel—lung cancer	0.00027	0.00142	CcSEcCtD
Scopolamine—Skin disorder—Paclitaxel—lung cancer	0.000268	0.00141	CcSEcCtD
Scopolamine—Abdominal pain—Irinotecan—lung cancer	0.000268	0.00141	CcSEcCtD
Scopolamine—Body temperature increased—Irinotecan—lung cancer	0.000268	0.00141	CcSEcCtD
Scopolamine—Hyperhidrosis—Paclitaxel—lung cancer	0.000267	0.0014	CcSEcCtD
Scopolamine—Drowsiness—Methotrexate—lung cancer	0.000265	0.00139	CcSEcCtD
Scopolamine—Hypotension—Etoposide—lung cancer	0.000263	0.00138	CcSEcCtD
Scopolamine—Pain—Cisplatin—lung cancer	0.000263	0.00138	CcSEcCtD
Scopolamine—Muscular weakness—Doxorubicin—lung cancer	0.000262	0.00138	CcSEcCtD
Scopolamine—Vomiting—Vinorelbine—lung cancer	0.000261	0.00137	CcSEcCtD
Scopolamine—Body temperature increased—Gemcitabine—lung cancer	0.000261	0.00137	CcSEcCtD
Scopolamine—Rash—Vinorelbine—lung cancer	0.000259	0.00136	CcSEcCtD
Scopolamine—Dermatitis—Vinorelbine—lung cancer	0.000259	0.00136	CcSEcCtD
Scopolamine—Hypotension—Paclitaxel—lung cancer	0.000258	0.00136	CcSEcCtD
Scopolamine—Headache—Vinorelbine—lung cancer	0.000257	0.00135	CcSEcCtD
Scopolamine—Conjunctivitis—Methotrexate—lung cancer	0.000257	0.00135	CcSEcCtD
Scopolamine—Dysphagia—Doxorubicin—lung cancer	0.000257	0.00135	CcSEcCtD
Scopolamine—Sweating—Methotrexate—lung cancer	0.000254	0.00133	CcSEcCtD
Scopolamine—Feeling abnormal—Cisplatin—lung cancer	0.000253	0.00133	CcSEcCtD
Scopolamine—Somnolence—Etoposide—lung cancer	0.00025	0.00132	CcSEcCtD
Scopolamine—Somnolence—Paclitaxel—lung cancer	0.000246	0.00129	CcSEcCtD
Scopolamine—Nausea—Vinorelbine—lung cancer	0.000244	0.00128	CcSEcCtD
Scopolamine—Body temperature increased—Cisplatin—lung cancer	0.000243	0.00128	CcSEcCtD
Scopolamine—Asthenia—Irinotecan—lung cancer	0.000243	0.00128	CcSEcCtD
Scopolamine—Fatigue—Etoposide—lung cancer	0.000243	0.00128	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000243	0.00128	CcSEcCtD
Scopolamine—Pain—Etoposide—lung cancer	0.000241	0.00127	CcSEcCtD
Scopolamine—Constipation—Etoposide—lung cancer	0.000241	0.00127	CcSEcCtD
Scopolamine—Dysuria—Doxorubicin—lung cancer	0.00024	0.00126	CcSEcCtD
Scopolamine—Dry mouth—Docetaxel—lung cancer	0.000239	0.00126	CcSEcCtD
Scopolamine—Fatigue—Paclitaxel—lung cancer	0.000238	0.00125	CcSEcCtD
Scopolamine—Asthenia—Gemcitabine—lung cancer	0.000237	0.00125	CcSEcCtD
Scopolamine—Pain—Paclitaxel—lung cancer	0.000236	0.00124	CcSEcCtD
Scopolamine—Constipation—Paclitaxel—lung cancer	0.000236	0.00124	CcSEcCtD
Scopolamine—Confusional state—Docetaxel—lung cancer	0.000236	0.00124	CcSEcCtD
Scopolamine—Pharyngitis—Methotrexate—lung cancer	0.000236	0.00124	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—lung cancer	0.000235	0.00123	CcSEcCtD
Scopolamine—Oedema—Docetaxel—lung cancer	0.000234	0.00123	CcSEcCtD
Scopolamine—Pruritus—Gemcitabine—lung cancer	0.000233	0.00123	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—lung cancer	0.000233	0.00122	CcSEcCtD
Scopolamine—Feeling abnormal—Etoposide—lung cancer	0.000232	0.00122	CcSEcCtD
Scopolamine—Nervous system disorder—Docetaxel—lung cancer	0.00023	0.00121	CcSEcCtD
Scopolamine—Drowsiness—Doxorubicin—lung cancer	0.000229	0.00121	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—lung cancer	0.000229	0.0012	CcSEcCtD
Scopolamine—Tachycardia—Docetaxel—lung cancer	0.000229	0.0012	CcSEcCtD
Scopolamine—Feeling abnormal—Paclitaxel—lung cancer	0.000228	0.0012	CcSEcCtD
Scopolamine—Skin disorder—Docetaxel—lung cancer	0.000227	0.0012	CcSEcCtD
Scopolamine—Dizziness—Irinotecan—lung cancer	0.000224	0.00118	CcSEcCtD
Scopolamine—Body temperature increased—Etoposide—lung cancer	0.000223	0.00117	CcSEcCtD
Scopolamine—Abdominal pain—Etoposide—lung cancer	0.000223	0.00117	CcSEcCtD
Scopolamine—Conjunctivitis—Doxorubicin—lung cancer	0.000223	0.00117	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—lung cancer	0.000222	0.00117	CcSEcCtD
Scopolamine—Asthenia—Cisplatin—lung cancer	0.000221	0.00116	CcSEcCtD
Scopolamine—Sweating—Doxorubicin—lung cancer	0.00022	0.00116	CcSEcCtD
Scopolamine—Hypotension—Docetaxel—lung cancer	0.000219	0.00115	CcSEcCtD
Scopolamine—Body temperature increased—Paclitaxel—lung cancer	0.000218	0.00115	CcSEcCtD
Scopolamine—Abdominal pain—Paclitaxel—lung cancer	0.000218	0.00115	CcSEcCtD
Scopolamine—Vomiting—Irinotecan—lung cancer	0.000215	0.00113	CcSEcCtD
Scopolamine—Rash—Irinotecan—lung cancer	0.000214	0.00112	CcSEcCtD
Scopolamine—Dermatitis—Irinotecan—lung cancer	0.000213	0.00112	CcSEcCtD
Scopolamine—Headache—Irinotecan—lung cancer	0.000212	0.00112	CcSEcCtD
Scopolamine—Vomiting—Gemcitabine—lung cancer	0.00021	0.0011	CcSEcCtD
Scopolamine—Bradycardia—Doxorubicin—lung cancer	0.000209	0.0011	CcSEcCtD
Scopolamine—Somnolence—Docetaxel—lung cancer	0.000208	0.00109	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—lung cancer	0.000208	0.00109	CcSEcCtD
Scopolamine—Rash—Gemcitabine—lung cancer	0.000208	0.00109	CcSEcCtD
Scopolamine—Dermatitis—Gemcitabine—lung cancer	0.000208	0.00109	CcSEcCtD
Scopolamine—Erythema—Methotrexate—lung cancer	0.000207	0.00109	CcSEcCtD
Scopolamine—Headache—Gemcitabine—lung cancer	0.000207	0.00109	CcSEcCtD
Scopolamine—Pharyngitis—Doxorubicin—lung cancer	0.000204	0.00107	CcSEcCtD
Scopolamine—Urinary tract disorder—Doxorubicin—lung cancer	0.000203	0.00107	CcSEcCtD
Scopolamine—Asthenia—Etoposide—lung cancer	0.000202	0.00106	CcSEcCtD
Scopolamine—Fatigue—Docetaxel—lung cancer	0.000202	0.00106	CcSEcCtD
Scopolamine—Urethral disorder—Doxorubicin—lung cancer	0.000202	0.00106	CcSEcCtD
Scopolamine—Nausea—Irinotecan—lung cancer	0.000201	0.00106	CcSEcCtD
Scopolamine—Pain—Docetaxel—lung cancer	0.0002	0.00105	CcSEcCtD
Scopolamine—Constipation—Docetaxel—lung cancer	0.0002	0.00105	CcSEcCtD
Scopolamine—Pruritus—Etoposide—lung cancer	0.000199	0.00105	CcSEcCtD
Scopolamine—Visual impairment—Doxorubicin—lung cancer	0.000198	0.00104	CcSEcCtD
Scopolamine—Asthenia—Paclitaxel—lung cancer	0.000198	0.00104	CcSEcCtD
Scopolamine—Nausea—Gemcitabine—lung cancer	0.000196	0.00103	CcSEcCtD
Scopolamine—Vomiting—Cisplatin—lung cancer	0.000196	0.00103	CcSEcCtD
Scopolamine—Pruritus—Paclitaxel—lung cancer	0.000195	0.00103	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—lung cancer	0.000195	0.00103	CcSEcCtD
Scopolamine—Rash—Cisplatin—lung cancer	0.000194	0.00102	CcSEcCtD
Scopolamine—Dermatitis—Cisplatin—lung cancer	0.000194	0.00102	CcSEcCtD
Scopolamine—Feeling abnormal—Docetaxel—lung cancer	0.000193	0.00101	CcSEcCtD
Scopolamine—Eye disorder—Doxorubicin—lung cancer	0.000192	0.00101	CcSEcCtD
Scopolamine—Flushing—Doxorubicin—lung cancer	0.000191	0.001	CcSEcCtD
Scopolamine—Dizziness—Etoposide—lung cancer	0.000186	0.00098	CcSEcCtD
Scopolamine—Vertigo—Methotrexate—lung cancer	0.000186	0.000977	CcSEcCtD
Scopolamine—Abdominal pain—Docetaxel—lung cancer	0.000185	0.000974	CcSEcCtD
Scopolamine—Body temperature increased—Docetaxel—lung cancer	0.000185	0.000974	CcSEcCtD
Scopolamine—Arrhythmia—Doxorubicin—lung cancer	0.000184	0.000967	CcSEcCtD
Scopolamine—Dizziness—Paclitaxel—lung cancer	0.000183	0.000961	CcSEcCtD
Scopolamine—Nausea—Cisplatin—lung cancer	0.000183	0.000961	CcSEcCtD
Scopolamine—Mental disorder—Doxorubicin—lung cancer	0.00018	0.000948	CcSEcCtD
Scopolamine—Vomiting—Etoposide—lung cancer	0.000179	0.000942	CcSEcCtD
Scopolamine—Erythema—Doxorubicin—lung cancer	0.000179	0.000942	CcSEcCtD
Scopolamine—Rash—Etoposide—lung cancer	0.000178	0.000934	CcSEcCtD
Scopolamine—Dermatitis—Etoposide—lung cancer	0.000177	0.000934	CcSEcCtD
Scopolamine—Headache—Etoposide—lung cancer	0.000177	0.000928	CcSEcCtD
Scopolamine—Vomiting—Paclitaxel—lung cancer	0.000176	0.000924	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000175	0.00092	CcSEcCtD
Scopolamine—Rash—Paclitaxel—lung cancer	0.000174	0.000916	CcSEcCtD
Scopolamine—Dermatitis—Paclitaxel—lung cancer	0.000174	0.000915	CcSEcCtD
Scopolamine—Headache—Paclitaxel—lung cancer	0.000173	0.00091	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—lung cancer	0.00017	0.000895	CcSEcCtD
Scopolamine—Vision blurred—Doxorubicin—lung cancer	0.000169	0.000888	CcSEcCtD
Scopolamine—Asthenia—Docetaxel—lung cancer	0.000168	0.000884	CcSEcCtD
Scopolamine—Nausea—Etoposide—lung cancer	0.000167	0.00088	CcSEcCtD
Scopolamine—Pruritus—Docetaxel—lung cancer	0.000166	0.000871	CcSEcCtD
Scopolamine—Nervous system disorder—Methotrexate—lung cancer	0.000166	0.000871	CcSEcCtD
Scopolamine—Agitation—Doxorubicin—lung cancer	0.000165	0.000866	CcSEcCtD
Scopolamine—Nausea—Paclitaxel—lung cancer	0.000164	0.000863	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—lung cancer	0.000164	0.000862	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—lung cancer	0.000163	0.000858	CcSEcCtD
Scopolamine—Vertigo—Doxorubicin—lung cancer	0.000161	0.000846	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—lung cancer	0.000158	0.00083	CcSEcCtD
Scopolamine—Dizziness—Docetaxel—lung cancer	0.000155	0.000814	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000151	0.000796	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—lung cancer	0.00015	0.000789	CcSEcCtD
Scopolamine—Dry mouth—Doxorubicin—lung cancer	0.000149	0.000784	CcSEcCtD
Scopolamine—Vomiting—Docetaxel—lung cancer	0.000149	0.000783	CcSEcCtD
Scopolamine—Rash—Docetaxel—lung cancer	0.000148	0.000777	CcSEcCtD
Scopolamine—Dermatitis—Docetaxel—lung cancer	0.000148	0.000776	CcSEcCtD
Scopolamine—Confusional state—Doxorubicin—lung cancer	0.000147	0.000775	CcSEcCtD
Scopolamine—Headache—Docetaxel—lung cancer	0.000147	0.000772	CcSEcCtD
Scopolamine—Oedema—Doxorubicin—lung cancer	0.000146	0.000769	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—lung cancer	0.000146	0.000765	CcSEcCtD
Scopolamine—Pain—Methotrexate—lung cancer	0.000144	0.000759	CcSEcCtD
Scopolamine—Nervous system disorder—Doxorubicin—lung cancer	0.000143	0.000754	CcSEcCtD
Scopolamine—Tachycardia—Doxorubicin—lung cancer	0.000143	0.00075	CcSEcCtD
Scopolamine—Skin disorder—Doxorubicin—lung cancer	0.000142	0.000747	CcSEcCtD
Scopolamine—Hyperhidrosis—Doxorubicin—lung cancer	0.000141	0.000743	CcSEcCtD
Scopolamine—Nausea—Docetaxel—lung cancer	0.000139	0.000732	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—lung cancer	0.000139	0.000732	CcSEcCtD
Scopolamine—Hypotension—Doxorubicin—lung cancer	0.000137	0.000718	CcSEcCtD
Scopolamine—Abdominal pain—Methotrexate—lung cancer	0.000133	0.000702	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—lung cancer	0.000133	0.000702	CcSEcCtD
Scopolamine—Somnolence—Doxorubicin—lung cancer	0.00013	0.000683	CcSEcCtD
Scopolamine—Fatigue—Doxorubicin—lung cancer	0.000126	0.000663	CcSEcCtD
Scopolamine—Pain—Doxorubicin—lung cancer	0.000125	0.000657	CcSEcCtD
Scopolamine—Constipation—Doxorubicin—lung cancer	0.000125	0.000657	CcSEcCtD
Scopolamine—Asthenia—Methotrexate—lung cancer	0.000121	0.000637	CcSEcCtD
Scopolamine—Feeling abnormal—Doxorubicin—lung cancer	0.00012	0.000633	CcSEcCtD
Scopolamine—Pruritus—Methotrexate—lung cancer	0.000119	0.000628	CcSEcCtD
Scopolamine—Body temperature increased—Doxorubicin—lung cancer	0.000116	0.000608	CcSEcCtD
Scopolamine—Abdominal pain—Doxorubicin—lung cancer	0.000116	0.000608	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—lung cancer	0.000112	0.000587	CcSEcCtD
Scopolamine—Vomiting—Methotrexate—lung cancer	0.000107	0.000564	CcSEcCtD
Scopolamine—Rash—Methotrexate—lung cancer	0.000106	0.00056	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—lung cancer	0.000106	0.000559	CcSEcCtD
Scopolamine—Headache—Methotrexate—lung cancer	0.000106	0.000556	CcSEcCtD
Scopolamine—Asthenia—Doxorubicin—lung cancer	0.000105	0.000552	CcSEcCtD
Scopolamine—Pruritus—Doxorubicin—lung cancer	0.000103	0.000544	CcSEcCtD
Scopolamine—Nausea—Methotrexate—lung cancer	0.0001	0.000527	CcSEcCtD
Scopolamine—Dizziness—Doxorubicin—lung cancer	9.66e-05	0.000508	CcSEcCtD
Scopolamine—Vomiting—Doxorubicin—lung cancer	9.29e-05	0.000489	CcSEcCtD
Scopolamine—Rash—Doxorubicin—lung cancer	9.21e-05	0.000485	CcSEcCtD
Scopolamine—Dermatitis—Doxorubicin—lung cancer	9.21e-05	0.000484	CcSEcCtD
Scopolamine—Headache—Doxorubicin—lung cancer	9.16e-05	0.000482	CcSEcCtD
Scopolamine—Nausea—Doxorubicin—lung cancer	8.68e-05	0.000457	CcSEcCtD
Scopolamine—CHRM3—Signaling by GPCR—IL2—lung cancer	1.2e-05	0.000138	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TERT—lung cancer	1.2e-05	0.000138	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TERT—lung cancer	1.2e-05	0.000137	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL2—lung cancer	1.19e-05	0.000136	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—PIK3CA—lung cancer	1.19e-05	0.000136	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TERT—lung cancer	1.19e-05	0.000136	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MDM2—lung cancer	1.18e-05	0.000135	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—RAF1—lung cancer	1.18e-05	0.000135	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—FGFR1—lung cancer	1.17e-05	0.000134	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—ERBB2—lung cancer	1.17e-05	0.000133	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—FGFR1—lung cancer	1.16e-05	0.000133	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—FGFR1—lung cancer	1.15e-05	0.000132	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MTOR—lung cancer	1.15e-05	0.000132	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CB—lung cancer	1.15e-05	0.000132	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HIF1A—lung cancer	1.15e-05	0.000132	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—POMC—lung cancer	1.15e-05	0.000132	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HIF1A—lung cancer	1.15e-05	0.000131	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—PIK3CA—lung cancer	1.14e-05	0.00013	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HIF1A—lung cancer	1.13e-05	0.00013	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MDM2—lung cancer	1.13e-05	0.00013	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—RAF1—lung cancer	1.13e-05	0.000129	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTP1—lung cancer	1.12e-05	0.000129	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CREBBP—lung cancer	1.12e-05	0.000128	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—ERBB2—lung cancer	1.12e-05	0.000128	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APOA1—lung cancer	1.11e-05	0.000127	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CXCL8—lung cancer	1.11e-05	0.000127	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APOA1—lung cancer	1.11e-05	0.000127	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CB—lung cancer	1.1e-05	0.000126	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MTOR—lung cancer	1.1e-05	0.000126	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KDR—lung cancer	1.1e-05	0.000126	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—HRAS—lung cancer	1.1e-05	0.000126	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KDR—lung cancer	1.1e-05	0.000125	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APOA1—lung cancer	1.09e-05	0.000125	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CAT—lung cancer	1.09e-05	0.000125	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KDR—lung cancer	1.08e-05	0.000124	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—AKT1—lung cancer	1.07e-05	0.000122	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CD—lung cancer	1.06e-05	0.000121	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CXCL8—lung cancer	1.06e-05	0.000121	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CASP3—lung cancer	1.06e-05	0.000121	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL2—lung cancer	1.06e-05	0.000121	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—HRAS—lung cancer	1.05e-05	0.00012	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL6—lung cancer	1.05e-05	0.00012	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ALB—lung cancer	1.05e-05	0.00012	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—TYMS—lung cancer	1.04e-05	0.000119	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTM1—lung cancer	1.03e-05	0.000118	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCND1—lung cancer	1.03e-05	0.000118	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—JUN—lung cancer	1.03e-05	0.000118	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—AKT1—lung cancer	1.02e-05	0.000117	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CASP3—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KIT—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CG—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—APC—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—NRAS—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL2—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—APC—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KIT—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CG—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—NRAS—lung cancer	1.01e-05	0.000116	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL6—lung cancer	1.01e-05	0.000115	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGF—lung cancer	1e-05	0.000115	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MMP9—lung cancer	1e-05	0.000115	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CG—lung cancer	9.99e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—APC—lung cancer	9.99e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KIT—lung cancer	9.99e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—NRAS—lung cancer	9.99e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGF—lung cancer	9.97e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CDKN1A—lung cancer	9.96e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PTEN—lung cancer	9.94e-06	0.000114	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGF—lung cancer	9.88e-06	0.000113	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCND1—lung cancer	9.86e-06	0.000113	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—JUN—lung cancer	9.84e-06	0.000113	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP1A1—lung cancer	9.77e-06	0.000112	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—AKT1—lung cancer	9.7e-06	0.000111	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ERCC2—lung cancer	9.69e-06	0.000111	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—MAPK3—lung cancer	9.69e-06	0.000111	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—MAPK3—lung cancer	9.66e-06	0.000111	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—POMC—lung cancer	9.63e-06	0.00011	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—POMC—lung cancer	9.6e-06	0.00011	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MMP9—lung cancer	9.57e-06	0.00011	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—MAPK3—lung cancer	9.57e-06	0.00011	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CDKN1A—lung cancer	9.54e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PTEN—lung cancer	9.52e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BRAF—lung cancer	9.51e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—POMC—lung cancer	9.51e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BRAF—lung cancer	9.48e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EP300—lung cancer	9.48e-06	0.000109	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6R—lung cancer	9.4e-06	0.000108	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BRAF—lung cancer	9.39e-06	0.000108	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CREBBP—lung cancer	9.38e-06	0.000107	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6R—lung cancer	9.37e-06	0.000107	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CREBBP—lung cancer	9.35e-06	0.000107	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—AKT1—lung cancer	9.29e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6R—lung cancer	9.28e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CREBBP—lung cancer	9.26e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CB—lung cancer	9.25e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—EGFR—lung cancer	9.22e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SRC—lung cancer	9.22e-06	0.000106	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—EGFR—lung cancer	9.19e-06	0.000105	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTGS2—lung cancer	9.16e-06	0.000105	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—EGFR—lung cancer	9.1e-06	0.000104	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EP300—lung cancer	9.08e-06	0.000104	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—VEGFA—lung cancer	8.98e-06	0.000103	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAP2K1—lung cancer	8.96e-06	0.000103	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAP2K1—lung cancer	8.93e-06	0.000102	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CD—lung cancer	8.9e-06	0.000102	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—STAT3—lung cancer	8.89e-06	0.000102	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CD—lung cancer	8.87e-06	0.000102	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—NRAS—lung cancer	8.87e-06	0.000102	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAP2K1—lung cancer	8.84e-06	0.000101	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SRC—lung cancer	8.83e-06	0.000101	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	8.81e-06	0.000101	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	8.78e-06	0.000101	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CD—lung cancer	8.78e-06	0.000101	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—KRAS—lung cancer	8.71e-06	9.98e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—PIK3CA—lung cancer	8.7e-06	9.96e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—KRAS—lung cancer	8.68e-06	9.95e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—KRAS—lung cancer	8.6e-06	9.85e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—VEGFA—lung cancer	8.6e-06	9.85e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—STAT3—lung cancer	8.51e-06	9.75e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MAPK3—lung cancer	8.49e-06	9.73e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—NRAS—lung cancer	8.49e-06	9.73e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—APOA1—lung cancer	8.39e-06	9.6e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MYC—lung cancer	8.26e-06	9.46e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MAPK3—lung cancer	8.13e-06	9.31e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EGFR—lung cancer	8.08e-06	9.25e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	8e-06	9.17e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTEN—lung cancer	7.99e-06	9.15e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	7.98e-06	9.14e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MDM2—lung cancer	7.97e-06	9.13e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MDM2—lung cancer	7.95e-06	9.1e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—RAF1—lung cancer	7.94e-06	9.1e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—RAF1—lung cancer	7.92e-06	9.07e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MYC—lung cancer	7.91e-06	9.06e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—PIK3CA—lung cancer	7.9e-06	9.05e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MDM2—lung cancer	7.87e-06	9.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ERBB2—lung cancer	7.86e-06	9e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—RAF1—lung cancer	7.84e-06	8.98e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ERBB2—lung cancer	7.83e-06	8.97e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ERBB2—lung cancer	7.76e-06	8.89e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MTOR—lung cancer	7.76e-06	8.88e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CB—lung cancer	7.76e-06	8.88e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EGFR—lung cancer	7.74e-06	8.86e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MTOR—lung cancer	7.73e-06	8.85e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CB—lung cancer	7.73e-06	8.85e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CG—lung cancer	7.66e-06	8.77e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MTOR—lung cancer	7.66e-06	8.77e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CB—lung cancer	7.66e-06	8.77e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KRAS—lung cancer	7.63e-06	8.74e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—EP300—lung cancer	7.62e-06	8.73e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CXCL8—lung cancer	7.45e-06	8.54e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CXCL8—lung cancer	7.43e-06	8.51e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—HRAS—lung cancer	7.4e-06	8.48e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—HRAS—lung cancer	7.38e-06	8.45e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CXCL8—lung cancer	7.36e-06	8.43e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—HRAS—lung cancer	7.31e-06	8.37e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KRAS—lung cancer	7.31e-06	8.37e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—POMC—lung cancer	7.29e-06	8.35e-05	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—AKT1—lung cancer	7.2e-06	8.25e-05	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—AKT1—lung cancer	7.18e-06	8.22e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CASP3—lung cancer	7.13e-06	8.17e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL2—lung cancer	7.12e-06	8.16e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CASP3—lung cancer	7.11e-06	8.14e-05	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—AKT1—lung cancer	7.11e-06	8.14e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL2—lung cancer	7.1e-06	8.13e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CREBBP—lung cancer	7.1e-06	8.13e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL6—lung cancer	7.09e-06	8.12e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL6—lung cancer	7.06e-06	8.09e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CASP3—lung cancer	7.04e-06	8.06e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL2—lung cancer	7.03e-06	8.05e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—PIK3CA—lung cancer	7.01e-06	8.03e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL6—lung cancer	7e-06	8.01e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCND1—lung cancer	6.94e-06	7.95e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JUN—lung cancer	6.93e-06	7.94e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCND1—lung cancer	6.92e-06	7.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JUN—lung cancer	6.91e-06	7.91e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCND1—lung cancer	6.85e-06	7.85e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JUN—lung cancer	6.84e-06	7.83e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TP53—lung cancer	6.78e-06	7.77e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MMP9—lung cancer	6.74e-06	7.72e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CD—lung cancer	6.73e-06	7.71e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MMP9—lung cancer	6.72e-06	7.7e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CDKN1A—lung cancer	6.72e-06	7.69e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—PIK3CA—lung cancer	6.71e-06	7.69e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PTEN—lung cancer	6.7e-06	7.68e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CDKN1A—lung cancer	6.7e-06	7.67e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PTEN—lung cancer	6.68e-06	7.65e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MMP9—lung cancer	6.65e-06	7.62e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ALB—lung cancer	6.64e-06	7.61e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CDKN1A—lung cancer	6.63e-06	7.59e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PTEN—lung cancer	6.62e-06	7.58e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—AKT1—lung cancer	6.54e-06	7.49e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—AKT1—lung cancer	6.52e-06	7.46e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TP53—lung cancer	6.5e-06	7.44e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—HRAS—lung cancer	6.49e-06	7.43e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—AKT1—lung cancer	6.45e-06	7.39e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EP300—lung cancer	6.39e-06	7.32e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EP300—lung cancer	6.37e-06	7.3e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EP300—lung cancer	6.31e-06	7.23e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SRC—lung cancer	6.21e-06	7.12e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—HRAS—lung cancer	6.21e-06	7.12e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL6—lung cancer	6.21e-06	7.11e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SRC—lung cancer	6.19e-06	7.1e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SRC—lung cancer	6.13e-06	7.03e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—VEGFA—lung cancer	6.05e-06	6.93e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—VEGFA—lung cancer	6.03e-06	6.91e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—STAT3—lung cancer	5.99e-06	6.86e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—NRAS—lung cancer	5.98e-06	6.85e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—VEGFA—lung cancer	5.98e-06	6.84e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—STAT3—lung cancer	5.97e-06	6.84e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—NRAS—lung cancer	5.96e-06	6.83e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL6—lung cancer	5.95e-06	6.81e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—STAT3—lung cancer	5.92e-06	6.78e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—NRAS—lung cancer	5.9e-06	6.76e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CB—lung cancer	5.87e-06	6.72e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS2—lung cancer	5.81e-06	6.66e-05	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—AKT1—lung cancer	5.73e-06	6.56e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MAPK3—lung cancer	5.73e-06	6.56e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MAPK3—lung cancer	5.71e-06	6.54e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MAPK3—lung cancer	5.65e-06	6.47e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PIK3CA—lung cancer	5.64e-06	6.46e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MYC—lung cancer	5.57e-06	6.38e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MYC—lung cancer	5.55e-06	6.36e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MYC—lung cancer	5.5e-06	6.3e-05	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—AKT1—lung cancer	5.49e-06	6.28e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGFR—lung cancer	5.45e-06	6.24e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGFR—lung cancer	5.43e-06	6.22e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGFR—lung cancer	5.38e-06	6.16e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KRAS—lung cancer	5.15e-06	5.89e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KRAS—lung cancer	5.13e-06	5.88e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KRAS—lung cancer	5.08e-06	5.82e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTEN—lung cancer	5.07e-06	5.81e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—EP300—lung cancer	4.83e-06	5.54e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—PIK3CA—lung cancer	4.73e-06	5.41e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—PIK3CA—lung cancer	4.71e-06	5.4e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—PIK3CA—lung cancer	4.67e-06	5.35e-05	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AKT1—lung cancer	4.6e-06	5.27e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TP53—lung cancer	4.57e-06	5.24e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TP53—lung cancer	4.56e-06	5.22e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TP53—lung cancer	4.51e-06	5.17e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HRAS—lung cancer	4.37e-06	5.01e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HRAS—lung cancer	4.36e-06	4.99e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HRAS—lung cancer	4.32e-06	4.95e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6—lung cancer	4.19e-06	4.79e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6—lung cancer	4.17e-06	4.78e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6—lung cancer	4.13e-06	4.73e-05	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—AKT1—lung cancer	3.86e-06	4.42e-05	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—AKT1—lung cancer	3.85e-06	4.41e-05	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—AKT1—lung cancer	3.81e-06	4.37e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PIK3CA—lung cancer	3.58e-06	4.1e-05	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AKT1—lung cancer	2.92e-06	3.35e-05	CbGpPWpGaD
